Novo Nordisk: oral semaglutide gets positive results
(CercleFinance.com) - Novo Nordisk's oral semaglutide drug performed well versus placebo in adults with moderate renal impairment, a serious complication of diabetes, the Danish drugmaker said on Monday.
A phase 3 trial achieved its primary endpoint, by demonstrating statistically significant and superior reductions in hemoglobin A1c (HbA1c) at week 26, Novo said.
Furthermore, people treated with oral semaglutide achieved statistically significant and superior reductions in body weight compared to placebo at week 26.
The trial investigating the efficacy and safety of the investigational tablet, taken once daily, included 324 people with type 2 diabetes and moderate renal impairment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A phase 3 trial achieved its primary endpoint, by demonstrating statistically significant and superior reductions in hemoglobin A1c (HbA1c) at week 26, Novo said.
Furthermore, people treated with oral semaglutide achieved statistically significant and superior reductions in body weight compared to placebo at week 26.
The trial investigating the efficacy and safety of the investigational tablet, taken once daily, included 324 people with type 2 diabetes and moderate renal impairment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.